- Investment bank and financial services company Raymond James has hired Andrew Gitkin
- Andrew Gitkin is going to become the managing director and co-head of the firm’s Health Care Investment Banking practice
Financial giant Raymond James announced it has hired Andrew Gitkin as managing director and co-head of the firm’s Health Care Investment Banking practice. Gitkin will be working closely with managing director Riley Sweat — who is co-leading the company’s health care investment banking efforts.
Specifically, Gitkin is going to focus on life sciences and biotechnology sector — which is an area in which he is deeply experienced and served for the last 15 years of his career. Gitkin is going to be based in Los Angeles in the investment banking division’s newly established office.
“Andrew is a highly regarded professional with an exceptional understanding of the biotech, life sciences and health care space,” said Jim Bunn — who is the president of Raymond James Global Equities and Investment Banking group. “He’s built an exceptional reputation in the sector and is adept at delivering results to clients, so we are thrilled to welcome him to our team and lead our efforts in this area.”
Gitkin is joining Raymond James from Piper Jaffray where he oversaw the West Coast biotech investment banking practice. And before joining Piper Jaffray, Gitkin was an investment banker with Moelis & Co.
Earlier in his career, Gitkin worked as a health care portfolio manager at both Tavistock Life Sciences and Saddle Point Asset Management. And he worked in the health care equity research at Salomon Smith Barney and Paine Webber/UBS. Plus he was awarded rankings by Institutional Investor and Greenwich Associates along with the recognition in Crain’s Business “40 under 40” reports. Gitkin earned a bachelor’s degree in business administration from Emory University’s Goizueta Business School.
“I am very excited to join my co-head Riley Sweat and the highly successful Raymond James Health Care Investment Banking team,” added Gitkin. “Over the last few years both the bankers and the equity research analysts have established a strong reputation in the life sciences area; and Raymond James, overall, has built a powerful global banking platform that I am looking forward to leveraging on behalf of my clients and helping to grow, particularly in the important West Coast market.”
